The goal of this series is to increase awareness of the indications and expected outcomes of Tzield (teplizumab) while emphasizing the importance of early screening for type 1 diabetes (T1D) associated autoantibodies, particularly in individuals with heightened familial risk-factors. The four-session series will explain the benefits and risks of screening for early T1D and summarize how appropriate follow up of a person who screens positive for early T1D is essential to preventing diabetic ketoacidosis at disease onset. Additionally, discussion will occur on which stages of T1D have FDA-approved treatment options other than insulin as well as listing the clinical treatment options for patients with early T1D. Learn from experts in the field on how to incorporate these tools into your practice in order to gain confidence and improve care for your patients.